Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. (2021). Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study. test, 17(1), 59-68. doi: 10.21608/blj.2021.194378
Radi Ali; Hala Galal El-Tantawi; Mohammed El-Sayed Rizk; Sabry Ali El-Naggar; Alaa Elmetwalli; Afrah Fatthi Salama. "Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study". test, 17, 1, 2021, 59-68. doi: 10.21608/blj.2021.194378
Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. (2021). 'Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study', test, 17(1), pp. 59-68. doi: 10.21608/blj.2021.194378
Ali, R., El-Tantawi, H., Rizk, M., El-Naggar, S., Elmetwalli, A., Salama, A. Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study. test, 2021; 17(1): 59-68. doi: 10.21608/blj.2021.194378